At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 426 enrolled
Drug / intervention
mometasone furoate +1 moredrug
Likely dose
mometasone furoate 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating mometasone furoate and Placebo for Seasonal Allergic Rhinitis. Completed, enrolled 426 participants.
Detailed Summary
This study is designed to assess the effectiveness of mometasone furoate nasal spay (MFNS) once daily (QD) compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total nasal symptom score and the total ocular symptom score.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMar 2007
Primary CompletionJun 2007
TodayJul 2026
First PostedMar 28, 2007
Enrollment StartMar 1, 2007
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 19.3 years ago
Interventions
mometasone furoatedrug
50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
Placebodrug
Two sprays in each nostril once daily in the morning